Dr. Jonathon Sedgwick joined AbbVie in 2021 as Vice President and Global Head of Discovery Research. In this role, he leads a global team of scientists who work to identify discover potential new treatments for a variety of diseases.diseases of high unmet medical need.
He is an immunologist whose pioneering contribution to the field was the identification of the dominant biological role of IL-23 as a major driver of autoimmune inflammation, and description of IL-23-driven Th17 CD4+ T cells. This work led stimulated to the discovery and development of multiple IL-23 and IL-17 focused therapeutics, including risankizumab.
Dr. Sedgwick’s career includes ten 10 years in academic research and over 2017 years in the biotechnology and biopharma sectorsindustry. He was most recently the Senior Vice President and Global Head, Cancer Immunology and Immune Modulation Research at Boehringer Ingelheim where he was responsible for the development of the immuno-oncology discovery and early clinical portfolio, and for immune-modulation research globally covering all therapy areas.
He has a Ph.D. in microbiology and immunology from the University of Western Australia and completed his post-doctoral education at the University of Oxford, United Kingdom with Don Mason, Neil Barclay and Alan Williams. He has published more thanover 120 peer-reviewed journal articles and book chapters.